TransMedics Group, Inc.TMDXEarnings & Financial Report
TransMedics Group, Inc. develops and commercializes innovative medical technologies for organ transplantation. Its flagship Organ Care System keeps donor organs viable during transport, improving transplant outcomes for heart, lung, liver and kidney recipients. It serves transplant centers and organ procurement organizations across North America, Europe and Asia-Pacific.
TMDX Q4 FY2025 Key Financial Metrics
Revenue
$160.8M
Gross Profit
$93.4M
Operating Profit
$21.3M
Net Profit
$105.4M
Gross Margin
58.1%
Operating Margin
13.2%
Net Margin
65.6%
YoY Growth
32.2%
EPS
$2.59
TransMedics Group, Inc. Q4 FY2025 Financial Summary
TransMedics Group, Inc. reported revenue of $160.8M (up 32.2% YoY) for Q4 FY2025, with a net profit of $105.4M (up 1436.9% YoY) (65.6% margin). Cost of goods sold was $67.3M, operating expenses totaled $72.1M.
Key Financial Metrics
| Total Revenue | $160.8M |
|---|---|
| Net Profit | $105.4M |
| Gross Margin | 58.1% |
| Operating Margin | 13.2% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
TransMedics Group, Inc. Q4 FY2025 revenue of $160.8M breaks down across 4 segments, led by Liver Product at $127.0M (79.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Liver Product | $127.0M | 79.0% |
| Heart Product | $26.0M | 16.2% |
| Other | $5.9M | 3.7% |
| Lung Product | $1.9M | 1.2% |
TransMedics Group, Inc. Revenue by Segment — Quarterly Trend
TransMedics Group, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Liver Product and Heart Product) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Liver Product | $127.0M | $107.9M | $115.9M | $108.7M |
| Heart Product | $26.0M | $27.4M | $32.2M | $26.3M |
| Other | $5.9M | $3.6M | $4.2M | $4.9M |
| Lung Product | $1.9M | $3.7M | $4.2M | $3.6M |
TransMedics Group, Inc. Annual Revenue by Year
TransMedics Group, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $605.5M).
TransMedics Group, Inc. Quarterly Revenue & Net Profit History
TransMedics Group, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $160.8M | +32.2% | $105.4M | 65.6% |
| Q3 FY2025 | $143.8M | +32.2% | $24.3M | 16.9% |
| Q2 FY2025 | $157.4M | +37.7% | $34.9M | 22.2% |
| Q1 FY2025 | $143.5M | +48.2% | $25.7M | 17.9% |
| Q4 FY2024 | $121.6M | +49.8% | $6.9M | 5.6% |
| Q3 FY2024 | $108.8M | +63.7% | $4.2M | 3.9% |
| Q2 FY2024 | $114.3M | +117.9% | $12.2M | 10.7% |
| Q1 FY2024 | $96.8M | +133.1% | $12.2M | 12.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $96.8M | $114.3M | $108.8M | $121.6M | $143.5M | $157.4M | $143.8M | $160.8M |
| YoY Growth | 133.1% | 117.9% | 63.7% | 49.8% | 48.2% | 37.7% | 32.2% | 32.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $723.8M | $758.6M | $785.6M | $804.1M | $837.5M | $890.5M | $946.0M | $1.07B |
| Liabilities | $564.4M | $568.7M | $575.7M | $575.5M | $571.2M | $572.4M | $590.8M | $595.3M |
| Equity | $159.5M | $189.9M | $209.9M | $228.6M | $266.3M | $318.1M | $355.2M | $473.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.4M | $25.7M | $6.9M | $19.7M | $-2.9M | $91.6M | $69.6M | $34.5M |